Hoffmann-La Roche
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Hoffmann-La Roche sits in the top decile of US sponsors by registered trial count (#36 of 15,742 sponsors by registered trial count).
Hoffmann-La Roche: 909 sponsored US clinical trials, 71 recruiting.
Hoffmann-La Roche sponsors 909 registered US clinical trials on ClinicalTrials.gov, 71 of them currently recruiting, and 654 completed. 372 of these trials are in Phase 3-4 (later-stage) and 492 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 13 trials.
Top-decile sponsor footprint
Hoffmann-La Roche ranks in the top decile of sponsors by registered trial count (#36 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
654 of 758 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
909 total, page 16 of 19
A Study of Induction Dosing With PEGASYS (Peginterferon Alfa-2a [40KD]) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C
NCT00394277
A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
NCT00423501
A Study of Subcutaneous Mircera for the Treatment of Anemia in Peritoneal Dialysis Patients.
NCT00442416
TESRA: (Treatment of Emphysema With a Gamma-Selective Retinoid Agonist)
NCT00413205
The Effect Of Oral Ibandronate In Male Osteoporosis
NCT00397839
A Long Term Extension of Study NC19453 Evaluating Safety and Efficacy of RO4607381
NCT00400439
A Study of Oseltamivir (Tamiflu) for the Seasonal Prophylaxis of Influenza in Immunocompromised Participants
NCT00412737
A Study of Tamiflu (Oseltamivir) for Seasonal Prophylaxis of Influenza in Children.
NCT00412555
A Study of Aleglitazar in Patients With Type 2 Diabetes
NCT00388518
A Drug-Drug Interaction Study of GK Activator (2) and Glyburide in Patients With Type 2 Diabetes.
NCT00388986
A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS With or Without COPEGUS in Patients With Chronic Hepatitis C (CHC) Genotype 1 Infection.
NCT00377182
A Study of Saquinavir/Ritonavir in Liver-Impaired Patients With HIV Infection.
NCT00435929
A Study to Provide RoActemra/Actemra (Tocilzumab) to Patients With Multicentric Castleman's Disease Who Demonstrated Benefit From Previous RoActemra/Actemra Treatment
NCT01183598
A Drug-Drug Interaction Study of GK Activator (2) and Simvastatin in Patients With Type 2 Diabetes.
NCT00377442
A Study of RO4607381 in Patients With Coronary Heart Disease (CHD) or a CHD Risk Equivalent.
NCT00353522
A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.
NCT00366379
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
NCT00337701
A Study Comparing Monthly Boniva (Ibandronate) and Weekly Risedronate in Women With Post-Menopausal Osteoporosis.
NCT00377234
A Study of P38 Inhibitor (4) Monotherapy in Patients With Active Rheumatoid Arthritis
NCT00303563
A Multiple Ascending Dose Study of R1507 in Patients With Advanced Solid Tumors.
NCT00400361
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
NCT00294515
BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1.
NCT00326963
A Study of Bone Turnover Markers in Post-Menopausal Women With Osteoporosis Treated With Monthly Boniva (Ibandronate)
NCT00303485
A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
NCT00316758
A Study of the Effect of Renal Impairment on the Activity of GK Activator (2) in Patients With Type 2 Diabetes.
NCT00368368
Pharmacogenetic Study of CellCept (Mycophenolate Mofetil) in Kidney Transplant Patients.
NCT00337493
A Study of Beta-Lactam in Hospitalized Patients With Skin and Skin Structure Infections
NCT00303589
A Study of Bonviva (Ibandronate) Once Monthly in Post-Menopausal Women With Osteopenia
NCT00129623
A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus
NCT00266240
A Study to Evaluate the Safety and Efficacy of Adding Enfuvirtide to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients With Prior Treatment Experience
NCT00487188
A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin
NCT00266253
A Study of P38 Inhibitor (4) in Patients With Active Rheumatoid Arthritis (RA) on Stable Methotrexate Therapy
NCT00316771
A Multiple Ascending Dose Study of R1530 in Patients With Advanced Solid Tumors.
NCT00493155
Heart Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Heart Transplant Recipients
NCT00121784
An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies
NCT00720798
XeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer
NCT00127933
Liver Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Sirolimus in Recipients of a Liver Transplant
NCT00118742
A Study To Assess the Quality and Strength of Bone in Women Participants With Osteoporosis Taking Oral Ibandronate Versus Placebo
NCT00148915
WAND Study - A Study to Evaluate Fuzeon (Enfuvirtide) Administered by a Needle-Free Injection Device in Patients With HIV.
NCT00233883
A Study to Assess the Efficacy of Intravenous/Oral Bondronat (Ibandronate) in Patients With Metastatic Bone Disease Experiencing Moderate to Severe Pain
NCT00099177
A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.
NCT00377637
A Study to Assess the Safety and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis
NCT00109408
A Study to Assess the Effect of RO4607381 in Patients With Relatively Low Levels of High Density Lipoprotein-Cholesterol (HDL-C)
NCT00697203
A Study to Assess the Efficacy of Intravenous Bondronat (Ibandronate) in Patients With Malignant and Painful Bone Disease
NCT00099203
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
NCT00111670
A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer
NCT00121836
A Study to Assess the Effect of Tocilizumab + Methotrexate on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis Currently on Methotrexate Therapy
NCT00106522
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
NCT00111631
A Study of R547 in Patients With Advanced Solid Tumors.
NCT00400296
GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection
NCT00105079
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 286 |
| Phase 2 | 206 |
| Phase 3 | 303 |
| Phase 4 | 69 |
Therapeutic Areas
What is open in the Hoffmann-La Roche pipeline
71 recruiting of 909 indexed (8% open); 654 completed (72%).
Phase mix: 372 late (III/IV) vs 492 early (I/II) (balanced across stages).
Top condition: Breast Cancer (13 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Hoffmann-La Roche: open-pipeline peers nationwide
Peers matched on 909 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
Hoffmann-La Roche sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 909 trials (± recruiting share)
- University of California, Los Angeles · 897 trials · 18% recruiting
- Indiana University · 890 trials · 18% recruiting
- Brigham and Women's Hospital · 937 trials · 15% recruiting
- Columbia University · 958 trials · 18% recruiting
Sponsors near 8% open enrollment (± trial volume)
- Boston Scientific Corporation · 8% recruiting · 280 trials
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 8% recruiting · 305 trials
- Novo Nordisk A/S · 8% recruiting · 431 trials
- National Institute of Allergy and Infectious Diseases (NIAID) · 8% recruiting · 2,006 trials
Related
What to do with this Hoffmann-La Roche page
909 registered trials is a research-attention snapshot, not an endorsement of Hoffmann-La Roche or any single study.
- 71 of Hoffmann-La Roche's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition Hoffmann-La Roche studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Hoffmann-La Roche pipeline card: 909 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.